Some studies have linked the popular weight-loss drugs with a potentially higher risk of eye problems and vision loss. Should ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will initiate a pivotal Phase IIb/III clinical trial for investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) ...

An intravitreal implant shows promise in enhancing visual function and retinal structure in diabetic retinopathy patients, according to recent research.

Q2 2025 Earnings Call Transcript August 5, 2025 Ocular Therapeutix, Inc. misses on earnings expectations. Reported EPS is $-0 ...

In patients with diabetic macular edema in both eyes, the port delivery system in one eye achieves a superior anatomical ...

Ophthalmology celebrates 50 years of groundbreaking innovations, highlighting anti-VEGF therapies, OCT imaging, and future ...

"Repeated intravitreal methotrexate injections appeared to facilitate retinal reattachment in children with complicated ...

Investigators reviewed the application of micropulse laser therapy in addition to aflibercept injections in patients with ...

Basel: Roche has announced new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term ...

Ixo-vec reduced anti-VEGF injection frequency and was well tolerated in patients with wet AMD. A phase 3 pivotal trial ...

In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

PER-001, delivered through a slow-release, dissolvable implant in the vitreous cavity of the eye, is designed to block ...